A new study is offering hope to thousands of Americans infected with two deadly diseases.

Hepatitis C is a leading cause of death among H-I-V patients.  Now, a new study published in this week's New England Journal of Medicine found that the combination of two hepatitis C therapies, Pegasys(R) and Copegus(R), produced the highest response rates ever reported in this patient population.  Doctor Douglas Dieterich, from Mount Sinai School of Medicine in New York, is the lead investigator of the apricot study:

"The APRICOT study was an enormous success.  It achieved a 40 percent sustained virologic response rate - that's cure rate - of the hepatitis C virus in H-I-V positive patients."

Rick Dillard has been H-I-V positive for nearly 20 years and was diagnosed with hepatitis C two years ago:

"I immediately started the Pegasys(R) combination therapy, and then now, after a year, I am cured."

CLICK HERE to download a transcript of this story:
https://www.cpwire.com/click.asp?feature=https://216.86.33.66/nejm.doc

CLICK HERE to download a multimedia (MP3) file of this story:
https://www.cpwire.com/click.asp?feature=https://216.86.33.66/nejm.mp3